The monolithic and huge investment in research and development (R&D) has helped boost the bottomline of Neimeth International Pharmaceutical plc, analysis of its financial statement shows. This focus strategy aimed at producing innovative and market penetrating product has also placed the compa
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp